
Substances of choice used in the previous 12 months were alcohol, nicotine vaping, and cannabis but the trends among the 8th, 10th, and 12th graders are very encouraging.

Substances of choice used in the previous 12 months were alcohol, nicotine vaping, and cannabis but the trends among the 8th, 10th, and 12th graders are very encouraging.

In the largest twin-sibling study to date of the inherited biological risk of PTSD, researchers found additive genetic and unique environmental effects contributed to the disorder.

New findings highlight the potential of this combination therapy as a new option for people with PTSD who have not responded to standard treatments.

A phase 1b and Phase 2 study are up next for the novel potential MDD treatment.

Intra-Cellular Therapies submitted an sNDA to the FDA for lumateperone for the treatment of MDD in adults as as adjunctive therapy to antidepressants.

Your daily dose of the clinical news you may have missed.

Approximately 70% of US adults surveyed hope their primary care clinician will ask about their mental health during an appointment, regardless of the presenting issue.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

The FDA warnings were intended to increase physician monitoring for suicidal thoughts and behaviors but have had dramatic unintended consequences.

Your daily dose of the clinical news you may have missed.

Findings from a systematic review and meta-analysis showed 1 in 3 youth with chronic pain were diagnosed with anxiety and 1 in 8 were diagnosed with depression.

A 14% increase in the rates of primary care safety planning within 2 weeks of a negative screening was associated 25% drop in the rate of attempted suicides.

Cobenfy, previously KarXT, is the first new agent with a novel mechanism of action for schizophrenia in more than 50 years, according to BMS.

Your daily dose of the clinical news you may have missed.

In a study of persons with moderate-to-severe atopic dermatitis, lebrikizumab monotherapy for 16 weeks resulted in improved quality of life and mental health.

Your daily dose of the clinical news you may have missed.

In a study of adolescents with obesity, symptoms of depression and eating disorders decreased over the course of a 52-week intensive behavioral intervention.

Your daily dose of the clinical news you may have missed.

The increase in the adult population with and at risk for dementia portends future burden among groups and communities with the fewest resources to cope.

Younger US veterans with PTSD and type 2 diabetes who no longer met criteria for PTSD were less likely to initiate insulin and had reduced odds of mortality.

Your daily dose of the clinical news you may have missed.

The FDA recently accepted the sNDA for brexpiprazole in combination with sertraline and set a PDUFA target action date for February 2025.

Following a decrease, suicide rates among US preteens increased annually by 8.2% from 2008 to 2022, according to a recent cross-sectional study.

Your daily dose of the clinical news you may have missed.